Skip to content
Review

Contemporary Evaluation and Management Strategies for Tricuspid Regurgitation.

Sep 2026 · Critical Pathways in Cardiology · 0 citations
Medicine

TL;DR

TR represents a complex and rapidly evolving area of cardiology that requires individualized assessment based on anatomy, hemodynamics, comorbidities, and the quality of available evidence.

Abstract

Background

Tricuspid regurgitation (TR) is a common but historically under-recognized valvular heart disease. Although mild to moderate TR was long considered benign, accumulating evidence indicates that clinically significant TR is associated with right ventricular failure, hepatic congestion, recurrent hospitalization, and increased mortality.

Aims

This review aims to provide a comprehensive overview of contemporary evaluation and management strategies for TR across its clinically relevant spectrum, with particular emphasis on severe disease and secondary mechanisms when discussing intervention.

Methods

Current literature was synthesized with a focus on TR classification, underlying mechanisms, imaging and hemodynamic assessment, risk stratification, device-related TR, and evolving therapeutic strategies, including both surgical and transcatheter approaches.

Results

Management paradigms have shifted toward earlier recognition and intervention, with echocardiography remaining central to diagnosis and procedural planning. While medical therapy is primarily supportive, advances in transcatheter edge-to-edge repair, annuloplasty systems, and transcatheter valve replacement have significantly expanded treatment options, particularly for patients at high surgical risk. Key determinants of therapeutic decision-making include pulmonary artery pressure, right ventricle-pulmonary artery coupling, right-sided chamber remodeling, surgical risk, and anatomic suitability.

Conclusion

TR represents a complex and rapidly evolving area of cardiology that requires individualized assessment based on anatomy, hemodynamics, comorbidities, and the quality of available evidence. Ongoing clinical trials and emerging therapies are expected to further refine treatment algorithms and future guideline recommendations.

View source

Similar papers

Review Aug 2026

Transcatheter tricuspid valve replacement for severe tricuspid regurgitation: current and future perspectives

ABSTRACT Introduction Severe tricuspid regurgitation (TR) is common, undertreated, and associated with significant morbidity and mortality. Transcatheter tricuspid valve replacement (TTVR) has emerged as a promising option for patients unsuitable for surgical repair or transcatheter edge-to-edge repair. Areas covered T...

G. Calamita, P. Leone, Ossama Elsaid et al. · 0 citations
Review Oct 2026

Treatment of Tricuspid Valve Disease.

In the landscape of valvular heart disease, the tricuspid valve has traditionally been dubbed the forgotten valve. However, over the last several years, studies have demonstrated that tricuspid valve disease is increasing in prevalence due to a growing aging population, and tricuspid regurgitation, in particular, is as...

E. Pliakos, S. Baron · 0 citations
Review Open access Aug 2026

Tricuspid Regurgitation and Leadless Pacemakers: A State-of-the-Art Review.

Tricuspid regurgitation (TR) is increasingly recognized as a major contributor to cardiovascular morbidity and mortality, with growing attention to its development and progression in patients with cardiac implantable electronic devices (CIEDs). While leadless pacemakers (LPMs) were introduced to eliminate transvalvular...

K. Abdelsayed, J. Sengupta, João L. Cavalcante et al. · 0 citations
Review Aug 2026

Contemporary Management of Failed Tricuspid Valve Prosthesis.

Failure of tricuspid valve prostheses is an increasingly encountered and complex clinical problem. Patients often present with advanced comorbidities, progressive right ventricular dysfunction, and prohibitive surgical risk. Despite growing burden, high-quality evidence and clear guideline-directed strategies remain li...

H. Allaham, Diljon S. Chahal, Mukta C. Srivastava et al. · 0 citations
Review Sep 2026

Post-TAVR LVOTO: Contemporary Management and Clinical Outcomes.

Transcatheter aortic valve replacement (TAVR) is an established therapy for severe aortic stenosis, yet dynamic left ventricular outflow tract obstruction (LVOTO) remains an uncommon but critical complication. We reviewed published reports of LVOTO after TAVR to delineate clinical patterns, imaging features, and manage...

N. Le, Nicholas Fanous, R. Abdo et al. · 0 citations
Aug 2026

Hemodynamic Changes After Transcatheter Valve Repair and Replacement for Tricuspid Regurgitation.

TEER was associated with a greater reduction in right atrial pressure and more favorable RV remodeling at 30 days, as opposed to TTVR, which achieved more complete and sustained elimination of tricuspid regurgitation with higher forward stroke volume.

Mohamad S. Alabdaljabar, Mohamed Elhadi, J. Thaden et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.